Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 7:06 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–19 of 19 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Macular Telangiectasia Type 2 (MacTel)
Interventions
NT-501/revakinagene taroretcel-lwey
Combination Product
Lead sponsor
Neurotech Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
285 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
23
States / cities
La Jolla, California • Los Angeles, California • Palo Alto, California + 19 more
Conditions
Telangiectasia
Interventions
Ranibizumab
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
18 Years to 80 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Macular Telangiectasia Type 2
Interventions
NT-501, Sham
Combination Product · Procedure
Lead sponsor
Neurotech Pharmaceuticals
Industry
Eligibility
21 Years to 80 Years
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
22
States / cities
Beverly Hills, California • Colorado Springs, Colorado • Atlanta, Georgia + 18 more
Completed Not applicable Interventional

MacTel Laser Study

NCT03321916
Conditions
Macular Telangiectasia
Interventions
577-nm PASCAL laser
Device
Lead sponsor
The Lowy Medical Research Institute Limited
Other
Eligibility
21 Years to 79 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Conditions
Macular Telangiectasia Type 2
Interventions
Serine, Fenofibrate
Dietary Supplement · Drug
Lead sponsor
The Lowy Medical Research Institute Limited
Other
Eligibility
21 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
8
States / cities
Atlanta, Georgia • Ann Arbor, Michigan • Cleveland, Ohio + 5 more
Conditions
Macular Telangiectasia Type 2 (MacTel)
Interventions
NT-501, Sham Procedure
Combination Product · Procedure
Lead sponsor
Neurotech Pharmaceuticals
Industry
Eligibility
21 Years to 80 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
16
States / cities
La Jolla, California • Los Angeles, California • Palo Alto, California + 13 more
Conditions
Telangiectasia
Interventions
Ranibizumab
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
18 Years to 80 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Retinal Diseases, Telangiectasis
Interventions
ranibizumab 2.0mg
Drug
Lead sponsor
Eye Center of Northern Colorado, P.C.
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Fort Collins, Colorado
Conditions
Macular Telangiectasia
Interventions
Ranibizumab
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
MacTel (Macular Telangiectasia) Type 2
Interventions
Ciliary neurotrophic factor (CNTF), Surgery
Biological · Procedure
Lead sponsor
Neurotech Pharmaceuticals
Industry
Eligibility
21 Years to 80 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
8
States / cities
Los Angeles, California • Miami, Florida • Atlanta, Georgia + 5 more
Conditions
Neovascularization
Interventions
Ranibizumab
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Macular Telangiectasia Type 2
Interventions
NT-501 CNTF implant
Combination Product
Lead sponsor
Neurotech Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
7
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Miami, Florida + 4 more
Conditions
Macular Telangiectasia Type 2 (MacTel)
Interventions
L-serine, Placebo
Drug · Other
Lead sponsor
The Lowy Medical Research Institute Limited
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
4
States / cities
La Jolla, California • Ann Arbor, Michigan • Cleveland, Ohio + 1 more
Conditions
Idiopathic Juxtafoveal Telangiectasia
Interventions
zeaxanthin
Drug
Lead sponsor
Paul S. Bernstein
Other
Eligibility
50 Years to 85 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Salt Lake City, Utah
Conditions
Telangiectasia
Interventions
Ranibizumab
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Idiopathic Juxtafoveal Telangiectasia
Interventions
NT-501 implant
Biological
Lead sponsor
Neurotech Pharmaceuticals
Industry
Eligibility
21 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
2
States / cities
Los Angeles, California • Cleveland, Ohio
Conditions
Macular Telangiectasia Type 2
Interventions
Ciliary neurotrophic factor (CNTF), Sham procedure, NT-501 Implant, NT-501 Implant procedure
Biological · Procedure · Device
Lead sponsor
Neurotech Pharmaceuticals
Industry
Eligibility
21 Years to 80 Years
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
8
States / cities
Los Angeles, California • Miami, Florida • Atlanta, Georgia + 5 more
Conditions
Macular Telangiectasia Type 2
Interventions
NT-501 CNTF Implant
Combination Product
Lead sponsor
Neurotech Pharmaceuticals
Industry
Eligibility
21 Years to 80 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
3
States / cities
Walnut Creek, California • Grand Rapids, Michigan • Bellaire, Texas
Conditions
Coats' Disease, Idiopathic Retinal Telangiectasia, Retinal Angiomatous Proliferation, Polypoidal Choroidal Vasculopathy, Pseudoxanthoma Elasticum, Pathological Myopia, Multi-focal Choroiditis, Rubeosis Iridis, Von Hippel Lindau Disease, BEST VITELLIFORM MACULAR DYSTROPHY, MULTIFOCAL (Disorder)
Interventions
ranibizumab injection (0.5 mg)
Drug
Lead sponsor
Manhattan Eye, Ear & Throat Hospital
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
2
States / cities
New York, New York